Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate
Durability Test Remains
Executive Summary
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
You may also be interested in...
GSK’s New Research Chief Begins Leadership With Expanded Genomics/AI Alliance
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.
Frontline Success Bolsters IO ‘Backbone’ Hopes For GSK’s Jemperli
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.